• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Characterisation of COVID-19 deaths by vaccination types and status in Malaysia between February and September 2021.

作者信息

Abdul Taib Nur Asheila, Baha Raja Dhesi, Teo Alvin Kuo Jing, Kamarulzaman Adeeba, William Timothy, Hs Arvinder-Singh, Mokhtar Siti Aisah, Ting Choo-Yee, Yap Wei Aun, Kim Michelle Chan Yoon, Edwin Amir Lidwina

机构信息

AINQA Health Sdn. Bhd., Malaysia.

Saw Swee Hock School of Public Health, National University of Singapore, National University Health System, Singapore.

出版信息

Lancet Reg Health West Pac. 2022 Jan;18:100354. doi: 10.1016/j.lanwpc.2021.100354. Epub 2022 Jan 1.

DOI:10.1016/j.lanwpc.2021.100354
PMID:35005667
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8720239/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35d3/8728580/9eb5343aa8cb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35d3/8728580/9eb5343aa8cb/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35d3/8728580/9eb5343aa8cb/gr1.jpg

相似文献

1
Characterisation of COVID-19 deaths by vaccination types and status in Malaysia between February and September 2021.2021年2月至9月马来西亚按疫苗类型和接种状况对新冠死亡病例的特征分析
Lancet Reg Health West Pac. 2022 Jan;18:100354. doi: 10.1016/j.lanwpc.2021.100354. Epub 2022 Jan 1.
2
PICK-ing Malaysia's Epidemic Apart: Effectiveness of a Diverse COVID-19 Vaccine Portfolio.剖析马来西亚的疫情：多样化新冠疫苗组合的有效性
Vaccines (Basel). 2021 Nov 24;9(12):1381. doi: 10.3390/vaccines9121381.
3
Phylogenomic analysis of SARS-CoV-2 from third wave clusters in Malaysia reveals dominant local lineage B.1.524 and persistent spike mutation A701V.马来西亚第三波疫情中 SARS-CoV-2 的系统基因组分析显示主要的本地谱系 B.1.524 和持续存在的刺突突变 A701V。
Trop Biomed. 2021 Sep 1;38(3):289-293. doi: 10.47665/tb.38.3.070.
4
Malaysia's third COVID-19 wave - a paradigm shift required.马来西亚的第三波 COVID-19 疫情——需要范式转变。
Med J Malaysia. 2021 Jan;76(1):1-4.
5
Estimating averted COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19 vaccination, Italy, January-September 2021.估算意大利 2021 年 1 月至 9 月因 COVID-19 疫苗接种而避免的 COVID-19 病例、住院、重症监护病房入院和死亡人数。
Euro Surveill. 2021 Nov;26(47). doi: 10.2807/1560-7917.ES.2021.26.47.2101001.
6
Rotavirus genotypes in Malaysia and universal rotavirus vaccination.马来西亚的轮状病毒基因型与普遍轮状病毒疫苗接种。
Hum Vaccin Immunother. 2012 Oct;8(10):1401-6. doi: 10.4161/hv.21577. Epub 2012 Sep 28.
7
COVID-19 Vaccination Intent, Perceptions, and Reasons for Not Vaccinating Among Groups Prioritized for Early Vaccination - United States, September and December 2020.2020 年 9 月和 12 月美国优先接种人群的 COVID-19 疫苗接种意愿、认知和不接种原因。
MMWR Morb Mortal Wkly Rep. 2021 Feb 12;70(6):217-222. doi: 10.15585/mmwr.mm7006e3.
8
COVID-19 vaccine safety monitoring in the Republic of Korea: February 26, 2021 to April 30, 2021.韩国2021年2月26日至2021年4月30日期间的新冠病毒疫苗安全性监测
Osong Public Health Res Perspect. 2021 Aug;12(4):264-268. doi: 10.24171/j.phrp.2021.0157. Epub 2021 Aug 13.
9
Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.辉瑞/生物科技和牛津/阿斯利康疫苗对沙特阿拉伯全国疫苗接种运动中真实环境下 COVID-19 发病率和死亡率的影响。
Eur Rev Med Pharmacol Sci. 2021 Nov;25(22):7185-7191. doi: 10.26355/eurrev_202111_27271.
10
The epidemiology of COVID-19 in ten Southeast Asian countries.COVID-19 在十个东南亚国家的流行病学情况。
Med J Malaysia. 2021 Nov;76(6):783-791.

引用本文的文献

1
Changing COVID-19 cases and deaths detection in Florida.佛罗里达州新冠病例和死亡人数检测变化。
PLoS One. 2024 Mar 28;19(3):e0299143. doi: 10.1371/journal.pone.0299143. eCollection 2024.
2
Narrative Review of the Evolution of COVID-19 Vaccination Recommendations in Countries in Latin America, Africa and the Middle East, and Asia.拉丁美洲、非洲、中东和亚洲国家新冠疫苗接种建议演变的叙述性综述
Infect Dis Ther. 2023 May;12(5):1237-1264. doi: 10.1007/s40121-023-00804-2. Epub 2023 Apr 25.
3
Palestinian analysis of COVID-19 vaccine compliance and reported death by vaccination type.

本文引用的文献

1
Characteristics of COVID-19-Related Deaths Among Older Adults in Malaysia.马来西亚老年人中与新冠病毒病相关死亡的特征
Malays J Med Sci. 2021 Aug;28(4):138-145. doi: 10.21315/mjms2021.28.4.14. Epub 2021 Aug 26.
2
Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19.mRNA疫苗和灭活疫苗针对新型冠状病毒肺炎的免疫原性比较
Lancet Microbe. 2021 Sep;2(9):e423. doi: 10.1016/S2666-5247(21)00177-4. Epub 2021 Jul 16.
巴勒斯坦对新冠疫苗接种依从性及按疫苗类型报告的死亡情况的分析。
J Family Med Prim Care. 2022 Nov;11(11):7362-7366. doi: 10.4103/jfmpc.jfmpc_1396_22. Epub 2022 Dec 16.
4
Hospitalization and Mortality by Vaccination Status among COVID-19 Patients Aged ≥ 25 Years in Bangladesh: Results from a Multicenter Cross-Sectional Study.孟加拉国25岁及以上新冠患者按疫苗接种状况划分的住院率和死亡率：一项多中心横断面研究的结果
Vaccines (Basel). 2022 Nov 23;10(12):1987. doi: 10.3390/vaccines10121987.
5
Burden of disease of COVID-19 in the department of Nariño, Colombia, 2020-2021.2020-2021 年哥伦比亚纳里尼奥省 COVID-19 疾病负担。
Rev Peru Med Exp Salud Publica. 2022 Jul-Sep;39(3):281-291. doi: 10.17843/rpmesp.2022.393.10947. Epub 2022 Dec 5.
6
How Does Vaccination against SARS-CoV-2 Affect Hospitalized Patients with COVID-19?接种针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的疫苗对新冠肺炎住院患者有何影响？
J Clin Med. 2022 Jul 5;11(13):3905. doi: 10.3390/jcm11133905.
7
SARS-CoV-2 Vaccination Coverage and Key Public Health Indicators May Explain Disparities in COVID-19 Country-Specific Case Fatality Rate Within European Economic Area.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗接种覆盖率和关键公共卫生指标或可解释欧洲经济区内各国新冠病毒病（COVID-19）特定国家病死率的差异。
Cureus. 2022 Mar 9;14(3):e22989. doi: 10.7759/cureus.22989. eCollection 2022 Mar.
8
Comparison of vaccine efficacy must be based on good clinical data.疫苗效力的比较必须基于良好的临床数据。
Lancet Reg Health West Pac. 2022 Mar 2;20:100410. doi: 10.1016/j.lanwpc.2022.100410. eCollection 2022 Mar.
9
Comparison of vaccine efficacy must be based on good clinical data-Authors' reply.疫苗效力的比较必须基于良好的临床数据——作者回复。
Lancet Reg Health West Pac. 2022 Feb 27;20:100413. doi: 10.1016/j.lanwpc.2022.100413. eCollection 2022 Mar.